Company Overview

Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for endocrine disorders with significant unmet medical needs. The company operates within the biotechnology and pharmaceutical research industry and has historically concentrated on rare and specialty endocrine diseases, particularly disorders involving adrenal hormone dysregulation. Spruce Biosciences does not generate commercial revenue and remains dependent on clinical development progress and capital markets financing.

The company’s primary historical development program has been tildacerfont (SPRB‑1), an oral, nonsteroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist investigated for congenital adrenal hyperplasia (CAH) and related endocrine conditions. Spruce Biosciences was founded in 2016 and completed its initial public offering in 2020, becoming listed on the NASDAQ under the ticker SPRB. Over time, the company has refined its strategy in response to clinical trial outcomes, including restructuring its development pipeline following mixed and unsuccessful late-stage trial results.

Business Operations

Spruce Biosciences operates as a single-reportable-segment biotechnology company, with activities centered on drug discovery, clinical development, and regulatory advancement. Its operations primarily involve preclinical research, clinical trial management, manufacturing coordination through third-party contractors, and regulatory engagement. The company does not maintain in-house manufacturing and relies on external partners for clinical supply and related services.

Operations are predominantly based in the United States, with clinical trials conducted across multiple domestic and international sites depending on study design. As a clinical-stage entity, Spruce Biosciences generates no product revenue and funds operations through equity offerings and cash reserves. Data inconclusive based on available public sources regarding any active revenue-generating collaborations or ongoing joint ventures.

Strategic Position & Investments

Strategically, Spruce Biosciences has focused on addressing rare endocrine diseases where targeted hormonal modulation could provide differentiated therapeutic benefit. Following the disclosure that tildacerfont did not meet primary endpoints in certain late-stage CAH trials, the company initiated cost-reduction measures and evaluated strategic alternatives, including pipeline reprioritization and potential business development opportunities.

The company previously expanded its portfolio through the acquisition of Virdis Pharma, a U.K.-based rare disease company, to broaden its endocrine-focused pipeline. However, public disclosures indicate that development priorities have shifted, and the current status of certain acquired programs remains uncertain. Data inconclusive based on available public sources regarding active late-stage development assets beyond previously disclosed programs.

Geographic Footprint

Spruce Biosciences is headquartered in Menlo Park, California, and maintains a primarily U.S.-based operational footprint. Clinical development activities have involved trial sites in North America and Europe, reflecting the global distribution of rare endocrine disease populations and regulatory requirements.

While the company does not maintain significant physical operations outside the United States, its clinical and regulatory activities give it a limited but meaningful international presence, particularly through outsourced research organizations and prior European-based acquisitions. The company does not report material international revenue.

Leadership & Governance

Spruce Biosciences is led by an executive team with experience in endocrinology, rare disease drug development, and public biotechnology company management. Leadership has emphasized scientific rigor, capital discipline, and strategic flexibility in response to clinical outcomes.

Key executives include:

• J. Paul Waymack – President and Chief Executive Officer
• Javier San Martin – Founder and Chief Scientific Officer

Public disclosures reference additional executive leadership and board oversight; however, specific role assignments beyond those listed above are data inconclusive based on available public sources. The company operates under a standard U.S. public company governance framework, with oversight by a board of directors and compliance with SEC reporting requirements, including Form 10‑K and Form 10‑Q filings.